Background: Mesenchymal stem cells (MSC) were shown to induce
beneficial effects in animal models of neurodegeneration and in pilot human
trials in multiple sclerosis and amyotrophic lateral sclerosis (ALS).
Aim: An open-label, clinical trial to evaluate the safety and efficacy
of repeated intrathecal administrations of autologous-MSC in ALS-patients.
Methods: The study included 20 subjects (age: 20–70) with definite
diagnosis of ALS and Amyotrophic Lateral Sclerosis Functional Rating Scale
Revised (ALSFRS-R) score of
Cite this article
476
Downloads
18
Citations
953
Views
Announcements
Open Access
Original Research
A phase II clinical trial with repeated intrathecal injections of autologous mesenchymal stem cells in patients with amyotrophic lateral sclerosis
Show Less
1
Unit of Neuroimmunology and Multiple Sclerosis Center and The Agnes-Ginges Center for Neurogenetics, Hadassah University Hospital, Ein-Kerem, 91120 Jerusalem, Israel
*Correspondence: dimitriosk@ekmd.huji.ac.il (Dimitrios Karussis)
Front. Biosci. (Landmark Ed) 2021, 26(10), 693–706;
https://doi.org/10.52586/4980
Submitted: 19 May 2021 | Revised: 24 August 2021 | Accepted: 27 August 2021 | Published: 30 October 2021
(This article belongs to the Special Issue Autologous and allogenic use of Stromal Vascular Fraction (SVF) and Decellularized Extracellular Matrices (ECM))
Copyright: © 2021 The Author(s). Published by BRI.
This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/).
Abstract
Keywords
Amyotrophic lateral sclerosis (ALS)
Mesenchymal stem cells (MSC)
Stem cells
Neuro-regeneration
Neuroprotection
Figures
Fig. 1.